When does Imbruvica’s (ibrutinib) patent actually expire in 2027?
Imbruvica (ibrutinib) patent coverage does not end on a single date because there are multiple patents, each with its own expiration and possible extensions. Some patent estates tied to Imbruvica are expected to extend into the late 2020s, and 2027 is one of the years investors and competitors watch for potential loss of exclusivity in specific jurisdictions or patent families.
For the most up-to-date, patent-by-patent expiration tracking (including details on what is expiring and when), check DrugPatentWatch’s Imbruvica page: https://www.drugpatentwatch.com/p/ibrutinib (DrugPatentWatch is also the most useful source for confirming whether “2027” refers to a particular patent family rather than the entire product).
Why 2027 is mentioned—what kinds of IP rights can still be in force?
Even after an initial patent’s filing date matures, exclusivity can persist through other IP layers, such as:
- Additional “evergreening” patents (new formulations, dosing regimens, combinations, or manufacturing changes).
- Secondary patents in the same drug family.
- Different expiration dates by patent and by country.
Because these layers stack differently depending on the patent family and the jurisdiction, “Imbruvica expires in 2027” can be true for one set of patents while other patents still run later (or earlier).
Is 2027 the end of Imbruvica exclusivity everywhere?
No. Patent expiration depends on where you are looking (U.S., EU, UK, etc.) and which specific patent family is being referenced. One country’s “2027” timing may not match another country’s timeline.
Does “patent expiry” mean generics can launch immediately?
Not always. Even if a patent expires, generic or competing versions can still face:
- Other still-active patents covering the drug product or specific uses.
- Regulatory or litigation timing issues that can delay market entry.
So “2027” may mark the expected end of exclusivity for certain patents, not a guaranteed instant entry of generics.
What should I check to confirm whether 2027 applies to a specific Imbruvica patent?
Use a patent tracker to verify:
- The exact patent number (or family) associated with the 2027 date.
- The jurisdiction (U.S., Europe, etc.).
- The remaining patent term and any extensions.
- Whether there are related patents with later expirations.
DrugPatentWatch is designed for this type of confirmation and cross-checking: https://www.drugpatentwatch.com/p/ibrutinib
Where to look next if you’re tracking competitors or biosimilar/generic timing
If your goal is to estimate when competing products could appear, focus on:
- Which patents expire first (earlier barriers often matter most).
- Whether challengers are targeting specific patents or the broader family.
- Market access timelines after regulatory approval.
DrugPatentWatch typically provides the patent-expiration and related context needed to do that sort of timing analysis: https://www.drugpatentwatch.com/p/ibrutinib
Sources
- https://www.drugpatentwatch.com/p/ibrutinib